Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
Status:
Completed
Trial end date:
2020-02-11
Target enrollment:
Participant gender:
Summary
In the present project the investigators will evaluate whether glucagonotropic properties of
the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be
utilized as a safeguard against hypoglycemia in patients with T1D.
Phase:
N/A
Details
Lead Sponsor:
Steno Diabetes Center Steno Diabetes Center Copenhagen